Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03567889 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
A Phase 3 study of Melanoma Stage IIIB and Melanoma Stage IIIC, sponsored by Philogen S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT03567889 is a Phase 3 study of Melanoma Stage IIIB and Melanoma Stage IIIC that is actively recruiting participants, run by Philogen S.p.A.. The registered enrollment target is 186 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT03567889, a Phase 3 study of Melanoma Stage IIIB and Melanoma Stage IIIC, is actively recruiting participants, sponsored by Philogen S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Conditions Studied
Interventions
- PROCEDURE Surgery
- DRUG Daromun
- DRUG Adjuvant therapy
Study Locations (20)
Pennsylvania
- St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd. - Easton
- Penn State Cancer Institute - Hershey
- Fox Chase Cancer Center 333 Cottman Avenue - Philadelphia
California
- UC San Diego Moores Cancer Center - La Jolla
- UC Irvine Health-Chao Family Comprehensive Cancer Center - Orange
New York
- Ambulatory Care Center at NYC Langarone Health - New York
- Memorial Sloan Kettering Cancer Center - Main Campus - Ney York
Arizona
- Mayo Clinic Hospital - Phoenix
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute, Emory university - Atlanta
Illinois
- Rush University Medical Center - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2018-09-20 |
| Est. Completion | 2031-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03567889
The ClinicalTrials.gov registry entry for NCT03567889 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philogen S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Melanoma Stage IIIB appearing as the primary indexed condition, and to 3 interventions - of which Surgery is the first listed.
NCT03567889 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Pennsylvania, California, New York.
Frequently Asked Questions
What is clinical trial NCT03567889 about?
NCT03567889 is a clinical study titled "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients". The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy...
What is the current status of trial NCT03567889?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2018-09-20. Estimated completion is 2031-12.
What conditions does trial NCT03567889 study?
This clinical trial studies the following conditions: Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID.
What interventions are being tested in trial NCT03567889?
The interventions under investigation include: Surgery (PROCEDURE), Daromun (DRUG), Adjuvant therapy (DRUG).
Who is sponsoring clinical trial NCT03567889?
This trial is sponsored by Philogen S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03567889 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.